Testosterone therapy for men over 50 is not the same protocol as testosterone therapy for men over 30. After 50, cardiovascular risk, prostate considerations, hematocrit elevation, and bone density all enter the clinical decision. This guide covers what changes in a testosterone protocol after 50, which dose adjustments matter most, and what a clinician monitors that they did not monitor at 35.
- Men over 50 typically start testosterone lower — 75-100mg weekly of testosterone cypionate — instead of the 120-150mg common at younger ages.
- Labs run every 3-6 months instead of annually, covering hematocrit, PSA, estradiol, and lipids.
- Testosterone does not cause prostate cancer, but it can accelerate existing disease, so PSA monitoring is mandatory.
- Hematocrit above 54% triggers dose reduction, a switch to transdermal formulation, or therapeutic phlebotomy — not discontinuation.
- Morning (7-9 AM) lab draws are essential, since testosterone declines 20-30% by afternoon.
- Prophylactic aromatase inhibitor use is discouraged; anastrozole should only be used when estradiol is confirmed elevated and symptomatic.
TL;DR
Testosterone therapy for men over 50 requires closer monitoring of hematocrit, PSA, cardiovascular markers, and bone density, but it remains an effective treatment for confirmed low testosterone. Typical starting doses are lower (75-100mg weekly of testosterone cypionate rather than 120-150mg), and follow-up labs run every 3-6 months instead of annually. Testosterone and muscle mass covers the body composition changes that testosterone therapy drives. GoodLife Health clinicians build age-adjusted protocols after reviewing labs. Verdict: testosterone therapy is safe and effective for men over 50 with confirmed low testosterone, but the protocol adjustments — lower starting dose, more frequent monitoring, cardiovascular awareness — are not optional.
Who this is for
This guide is for men aged 50-70 with symptoms of low testosterone (fatigue, low libido, reduced muscle mass, mood changes) and a confirmed lab diagnosis: total testosterone below 350 ng/dL on a morning draw, or free testosterone below the age-adjusted optimal range. It is especially relevant for men who also have metabolic syndrome, insulin resistance, or elevated BMI, because testosterone therapy interacts with these conditions.
What to look for in testosterone therapy for men over 50
Cardiovascular screening before starting
Before prescribing testosterone, a clinician should check blood pressure, lipid panel, and cardiovascular risk factors. The FDA added a warning about cardiovascular risk to testosterone labels in 2015, and the evidence through 2026 is nuanced: testosterone therapy in men with genuinely low testosterone does not increase cardiovascular events and may reduce them, but starting testosterone in men with normal levels or pre-existing cardiovascular disease without monitoring is riskier. Testosterone replacement therapy for men covers the cardiovascular data in detail. Verdict: a clinician who starts testosterone without checking blood pressure and lipids first is cutting a corner.
Hematocrit monitoring at every lab draw
Testosterone therapy stimulates red blood cell production. In men over 50, hematocrit can rise above 54%, which increases blood viscosity and theoretical thrombotic risk. A clinician should check hematocrit at baseline, at 6-8 weeks, and every 3-6 months thereafter. If hematocrit exceeds 54%, the clinician may reduce the dose, switch to a transdermal formulation, or recommend therapeutic phlebotomy. How to tell if your hormone therapy dose needs adjusting covers the hematocrit management protocol.
PSA and prostate monitoring
The relationship between testosterone therapy and prostate cancer is more nuanced than earlier guidance suggested. Testosterone does not cause prostate cancer, but it can accelerate existing prostate cancer. A clinician should check PSA at baseline and at 3-6 month intervals. A rising PSA does not mean stop testosterone — it means investigate. Most rising PSAs in men on testosterone are benign (BPH), but the investigation is mandatory.
A rising PSA does not mean stop testosterone — it means investigate. Most rising PSAs in men on testosterone are benign (BPH), but the investigation is mandatory.
Lower starting doses with slower titration
Men over 50 typically start at 75-100mg of testosterone cypionate weekly, compared to 100-150mg for younger men. The lower starting dose accommodates the higher hematocrit baseline in older men and allows the clinician to assess cardiovascular response before escalating. Dose adjustments happen at 8-week intervals based on labs, not symptoms alone.
Bone density assessment at baseline
Men over 50 on testosterone therapy should have a DEXA scan at baseline if risk factors warrant it. Testosterone helps maintain bone density, and low testosterone is a risk factor for osteoporosis in men. Establishing a baseline lets the clinician track whether therapy is improving or maintaining bone density over time.
Estradiol management
Testosterone aromatizes to estradiol, and in men over 50 with higher body fat, aromatization increases. Elevated estradiol causes breast tenderness, water retention, and mood changes. A clinician should check estradiol alongside testosterone at follow-up labs. If estradiol is elevated, the first intervention is often dose reduction rather than adding an aromatase inhibitor.
Top picks: testosterone therapy approaches for men over 50
Testosterone cypionate injections (75-100mg weekly) — Buy. The standard first-line option for men over 50 with confirmed low testosterone. Injectable testosterone allows precise dose control and weekly dosing minimizes peak-trough fluctuations. GoodLife Health clinicians start here for most men over 50. Buy if your labs confirm low testosterone and your cardiovascular screening is clear.
Transdermal testosterone (gel or cream) — Consider. Transdermal formulations produce more stable levels and lower hematocrit elevation than injections. They are a good option for men who have elevated hematocrit on injections or who prefer daily application. The trade-off is that transdermal testosterone often produces lower total testosterone levels than injections. Consider if injections cause hematocrit issues or you prefer daily application.
Testosterone pellets — Consider. Pellets provide 3-5 months of stable testosterone without daily or weekly dosing. Testosterone pellet dosing for men covers the pellet protocol. For men over 50, pellets can work but require careful dose calculation because the dose cannot be adjusted mid-cycle if hematocrit rises. Consider if you want long-acting dosing and your hematocrit is well-controlled.
Compounded testosterone formulations — Skip for first-line. Compounded creams, troches, or injections are options when standard formulations do not work, but quality control varies. Start with FDA-approved formulations and consider compounded options only if the standard approach fails. Skip as a first-line choice.
What to avoid
- Starting testosterone without a morning (7-9 AM) lab draw. Testosterone declines 20-30% from morning to afternoon. An afternoon draw may show "low" testosterone when morning levels are normal.
- Prescribing testosterone without checking hematocrit, PSA, and lipids at baseline. These are the three markers that determine whether testosterone therapy is safe for men over 50.
- Using estradiol blockers (aromatase inhibitors) prophylactically. Anastrozole should only be used when estradiol is confirmed elevated and symptomatic, not as a preventive measure. Prophylactic AI use suppresses estradiol below healthy levels, which harms bone density and cardiovascular health.
Verdict comparison
Verdict comparison
Starting dose, hematocrit risk, and monitoring by approach
| Approach | Starting dose | Hematocrit risk | Monitoring frequency | Verdict |
|---|---|---|---|---|
| TC injections | 75-100mg/wk | Moderate | Every 3-6 months | Buy |
| Transdermal gel | Variable | Lower | Every 3-6 months | Consider |
| Pellets | Calculated | Moderate | Every 4-5 months | Consider |
| Compounded | Varies | Varies | Varies | Skip for first-line |
FAQ
Is testosterone therapy safe for men over 50? Yes, for men with confirmed low testosterone and clean cardiovascular screening. The protocol requires more monitoring than for younger men (hematocrit, PSA, lipids every 3-6 months), but the evidence through 2026 supports its safety and effectiveness in appropriately selected patients.
What dose of testosterone should a man over 50 start with? Most clinicians start men over 50 at 75-100mg of testosterone cypionate weekly, lower than the 100-150mg typical for younger men. The lower starting dose accommodates age-related cardiovascular and hematocrit considerations.
Does testosterone therapy increase prostate cancer risk? Testosterone does not cause prostate cancer, but it can accelerate existing prostate cancer. PSA monitoring at 3-6 month intervals catches any changes early. Most PSA elevations in men on testosterone are benign (BPH), not cancer.
How often should a man over 50 get labs on testosterone therapy? Every 3-6 months: total and free testosterone, estradiol, hematocrit, PSA, and lipid panel. Annual monitoring is insufficient for men over 50.
Does testosterone therapy help with bone density in men over 50? Yes. Low testosterone is a risk factor for osteoporosis in men. Restoring testosterone to optimal range helps maintain bone density. A DEXA scan at baseline establishes whether bone density is already compromised.
What happens if hematocrit rises on testosterone therapy? Hematocrit above 54% triggers dose reduction, a switch to transdermal formulation, or therapeutic phlebotomy. This is a manageable side effect, not a reason to stop therapy.
Can men over 50 take testosterone if they have cardiovascular disease? It depends on the specific cardiovascular condition and stability. A cardiologist and the prescribing clinician should co-manage. Testosterone in men with confirmed deficiency does not increase cardiovascular events in the 2026 evidence, but pre-existing disease requires careful evaluation.
The single most important adjustment for men over 50 on testosterone therapy is not the dose — it is the monitoring frequency.
One last thing
The single most important adjustment for men over 50 on testosterone therapy is not the dose — it is the monitoring frequency. A clinician who checks hematocrit, PSA, and estradiol annually instead of every 3-6 months is not providing age-appropriate care. The risks of testosterone therapy after 50 are manageable, but only if they are monitored at the interval the evidence supports. Annual labs are for stable patients at the maintenance dose, not for the first 12 months of therapy.
Related guides
References
- Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. 2018. doi.org/10.1210/jc.2018-00229